We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 472

When is a little knowledge a dangerous thing? When it is used to disqualify in-house counsel

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • February 28 2014

A powerful tool in the litigation arsenal is the bringing of a motion to remove counsel from a file, either because she possesses disqualifying

Federal Court dismisses application for a prohibition order in respect of PATADAY eye drop solution

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 18 2014

This case concerns a proposed generic version of the brand name drug PATADAY, an eye drop solution used to treat allergic and inflammatory eye

Updating the plant breeder’s rights regime in Canada

  • Miller Thomson LLP
  • -
  • Canada
  • -
  • March 3 2014

Development of a new seed variety requires a substantial investment of time and money. The quest to discover new traits and improve plant performance

Product specificity requirement trumps patent construction for listing

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 5 2014

Lilly sought to list Canadian Patent No. 2,379,329 on the patent register for their product TRIFEXIS. The Minister refused, stating that the patent

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

First Canadian decision on biologics: a new era begins

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • February 10 2014

In AbbVie v. Janssen, the Federal Court of Canada recently handed down the first Canadian decision regarding a patent on biologic drugs. Before that

Good news for antibody patent applications in Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 27 2014

Patentees in the antibody arts in Canada have long been dogged by policy-based objections to claims that seek protection that is broader than the

Prohibition application re olopatadine patent dismissed for lack of sound prediction

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 21 2014

In her February 14th decision of Alcon Canada Inc v. Cobalt Pharmaceuticals Company(2014 FC 149), Justice Gleason of the Federal Court denied Alcon's

Federal Court upholds validity of patent for escitalopram (CIPRALEX)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 19 2013

Apotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is

Principles of comity should not override fairness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 26 2014

Cobalt brought a motion pursuant to s. 6(5) of the NOC Regulations, to dismiss the proceeding as an abuse of process. The Court dismissed the motion